FDA Inspection 1160831 — Rentschler Biopharma SE
The FDA completed an inspection of Rentschler Biopharma SE on Feb 26, 2021 in Laupheim. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Feb 26, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Laupheim (Germany)
Additional details
Mutual Recognition Agreement (MRA)